Saudi’s Wa’ed Ventures Leads $10M Funding to Propel Kure Cells into Biotech Hub

Editorial Team

Last updated 24-10-2025

3 min

Kure Cells secures $10 million from Wa’ed Ventures to expand in Saudi Arabia.

The investment includes U.

backers like Komel Healthcare and NantBio.

Kure's "Ultra-Fast CAR" tech shortens T cell engineering to under 24 hours.

Saudi aims to become a regional biotech hub with local research and collaboration.

There’s been a bit of a buzz lately around a fascinating biotech story — one that, I reckon, says a lot about how Saudi investment is shaping the future of advanced medicine. Kure Cells, a U.S.-based biotechnology company, has just secured a $10 million pre‑Series A round, led by Wa’ed Ventures. The move isn’t just about cash; it’s about collaboration and a rather bold step into the Saudi innovation scene.

From what’s been shared publicly, the round also drew backing from Komel Healthcare, U.S. pharmaceutical player NantBio, and several American investors under the US93 group. The fresh funding will help Kure Cells expand its footprint into Saudi Arabia, setting up research, development, and manufacturing sites. The idea is to work hand‑in‑hand with local researchers to tailor its “Ultra‑Fast CAR” platform to regional health systems.

Now, for anyone not deep in biotech jargon, this UF‑CAR technology is pretty ground‑breaking. It allows for engineering a patient’s T cells — the immune fighters used in CAR‑T therapy — in under 24 hours. Normally, that process takes weeks. And let’s be honest, time matters when you’re dealing with cancer treatment. Faster turnaround also means lower production costs and potentially broader access to these life‑saving therapies.

The company was founded by scientists David Wald and Sayer Alfuraydi, who seem determined to make cell therapy more efficient without compromising safety or clinical quality. It feels spot on that Saudi Arabia, through Wa’ed Ventures, is throwing its weight behind this. The arrangement aligns perfectly with the Ministry of Investment’s and the Research, Development and Innovation Authority’s ambitions to make the Kingdom a regional hub for biotech advancement.

Of course, big ambitions come with big execution challenges — setting up advanced labs and building a research ecosystem is no walk in the park. But if things go to plan, this could be one of those moments when investment genuinely bridges continents for the sake of science. And, speaking from my Arageek corner, supporting this kind of cross‑border innovation is exactly what energises us here — it’s about giving brilliant ideas the right soil to grow.

That said, success in biotech is rarely a straight line. Regulations, logistics, and local partnerships all have to click into place. Still, I wouldn’t bet against this one; the momentum is unmistakable, and the blend of local insight with U.S. expertise could be just the recipe Saudi’s innovation drive needs. Well… it’s definately a story to keep an eye on.

🚀 Got exciting news to share?

If you're a startup founder, VC, or PR agency with big updates—funding rounds, product launches 📢, or company milestones 🎉 — AraGeek English wants to hear from you!